CA Patent

CA3243789A1 — Methods of treating systemic lupus erythematosus

Assigned to AbbVie Inc · Expires 2024-02-01 · 2y expired

What this patent protects

"This disclosure relates to methods for treating systemic lupus erythematosus (SLE) using the selective JAK1 inhibitor, upadacitinib."

USPTO Abstract

"This disclosure relates to methods for treating systemic lupus erythematosus (SLE) using the selective JAK1 inhibitor, upadacitinib."

Drugs covered by this patent

Patent Metadata

Patent number
CA3243789A1
Jurisdiction
CA
Classification
—
Expires
2024-02-01
Drug substance claim
No
Drug product claim
No
Assignee
AbbVie Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.